<!DOCTYPE html><html><head><style>
      /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      /* Create a title page with a full-bleed background and no header */
      #title-page {
        page: title-page;
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #000000;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Times New Roman';
        color: #000000;
      }
    </style>
    <link href='https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&display=swap' rel='stylesheet'>
    </style></head><body>
      <div id="title-page" class="page">
        <h1>Simple Test 1</h1>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
      <div id="toc-page" class="page">
        <div id="table-of-contents">
          <a href="#section-0"></a><a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a><a href="#section-15"></a>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    <div class="page"><table><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Confidentiality Statement:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Sponsor Confidentiality Statement</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Full Title:</p></th><td style="vertical-align: top; text-align: left"><p>Something Very Official</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Full Title</span><br/><span style="color: #FA8072">USDM: StudyProtocolDocumentVersion/@officialTitle</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Acronym:</p></th><td style="vertical-align: top; text-align: left"><p>SIMPLE</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter trial Acronym</span><br/><span style="color: #FA8072">USDM: StudyVersion/@studyAcronym</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Protocol Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>AP1234</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Protocol Identifier</span><br/><span style="color: #FA8072">USDM: StudyIdentifier/@studyIdentifier</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Original Protocol:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Original protocol</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Number:</p></th><td style="vertical-align: top; text-align: left"><p>1</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Version Number</span><br/><span style="color: #FA8072">USDM: StudyVersion/@studyVersion</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Date:</p></th><td style="vertical-align: top; text-align: left"><p>2023-01-01</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Version Date</span><br/><span style="color: #FA8072">USDM: StudyVersion/GovernanceDate[@type.code=C132352]/@dateValue</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>4</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Amendment Identifier</span><br/><span style="color: #FA8072">USDM: StudyVersion/StudyAmendment/@number</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Scope:</p></th><td style="vertical-align: top; text-align: left"><p>Global</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Amendment Scope</span><br/><span style="color: #FA8072">USDM: StudyVersion/StudyAmendment/SubjectEnrollment[@type/@code=C68846]/Code/@decode</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Codes(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Compound Code(s)</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Name(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Nonproprietary Name(s), Enter Proprietary Name(s)</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Phase:</p></th><td style="vertical-align: top; text-align: left"><p>Phase III Trial</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Trial Phase</span><br/><span style="color: #FA8072">USDM: Code/@decode</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Short Title:</p></th><td style="vertical-align: top; text-align: left"><p>Something Brief</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Trial Short Title</span><br/><span style="color: #FA8072">USDM: StudyProtocolDocumentVersion/@briefTitle</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Name and Address:</p></th><td style="vertical-align: top; text-align: left"><p>ACME Pharma<br/>Somewhere, In a City, In a District, In a big state, 12345, France</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Sponsor Name, Enter Sponsor Legal Address</span><br/><span style="color: #FA8072">USDM: Organization/@name, Address/@text</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Regulatory Agency Identifier Number(s):</p></th><td style="vertical-align: top; text-align: left"><p>NCT12345678, EU12345, IND12345, WHO12345</p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: EU CT Number, IDE Number, FDA IND Number, JRCT Number, NCT Number, NMPA IND Number, WHO/UTN Number, Other Regulatory Agency Identifier Number</span><br/><span style="color: #FA8072">USDM: StudyIndentifier[Organization/@type.code=C188863|C93453]/@studyIdentifier</span></i></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Spondor Approval Date:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr bgcolor="#F2F4F4"><td colspan="2" style="vertical-align: top; text-align: left"><p style="vertical-align: top; text-align: left; color: #2AAA8A; font-size: 12px"><i><span style="color: #2AAA8A">M11: Enter Approval Date or state location where information can be found</span><br/><span style="color: #FA8072">USDM: No mapping path</span></i></p></td></tr></table></div><div class="page"><h1 id="section-1">1&nbspPROTOCOL SUMMARY</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-2">2&nbspINTRODUCTION</h1><div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-3">3&nbspTRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS</h1><div></div><div class=""><table><tr><td style="vertical-align: top; text-align: left"><p>The primary efficacy objective for this study is to evaluate the efficacy of TCZ compared with placebo in combination with SOC for the treatment of severe COVID-19 pneumonia</p></td><td style="vertical-align: top; text-align: left"><p>Clinical status assessed using a 7-category ordinal scale at Day 28</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>The secondary efficacy objective for this study is to evaluate the efficacy of TCZ compared with placebo in combination with SOC for the treatment of severe COVID-19 pneumonia over the age of 18 years</p></td><td style="vertical-align: top; text-align: left"><p>Time to clinical improvement (TTCI) defined as a National Early Warning Score 2 (NEWS2) of &lt;=2 maintained for 24 hours</p><p>Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status</p></td></tr></table></div></div><div class="page"><h1 id="section-4">4&nbspTRIAL DESIGN</h1><div></div><div class=""><div></div><div class=""><div></div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-5">5&nbspTRIAL POPULATION</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table><tr><td style="vertical-align: top; text-align: left"><p>1</p></td><td style="vertical-align: top; text-align: left"><p>Subjects shall be between 18 years and 40 years</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>2</p></td><td style="vertical-align: top; text-align: left"><p>Subjects shall be between 18 years and [max_agexxx]</p></td></tr></table></div><div class=""><p>Patients may be excluded in the study for <strong>any</strong> of the following reasons:</p><table><tr><td style="vertical-align: top; text-align: left"><p>1</p></td><td style="vertical-align: top; text-align: left"><p>Subjects has been treated with Drug A at any time in the past</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>2</p></td><td style="vertical-align: top; text-align: left"><p>Pick up activity Demographics</p></td></tr></table></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-6">6&nbspTRIAL INTERVENTION AND CONCOMITANT THERAPY</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div><p>Blinding and unblinding text here please</p></div></div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div></div><div class="page"><h1 id="section-7">7&nbspDISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL</h1><div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-8">8&nbspTRIAL ASSESSMENTS AND PROCEDURES</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div></div></div><div class="page"><h1 id="section-9">9&nbspSTATISTICAL CONSIDERATIONS</h1><div></div><div class=""><div></div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-10">10&nbspGENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-11">11&nbspGENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-12">12&nbspAPPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY</h1><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-13">13&nbspAPPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS</h1><div></div><div class=""><div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class=""><div></div></div><div class=""><div></div></div><div class=""><div></div></div></div><div class="page"><h1 id="section-14">14&nbspAPPENDIX: GLOSSARY OF TERMS</h1><div></div></div><div class="page"><h1 id="section-15">15&nbspAPPENDIX: REFERENCES</h1><div></div></div></body></html>